Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 1.00 |
| ▸ | BACE2 | Q9Y5Z0 | 12/20 | 1.00 |
| ▸ | CTSD | P07339 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6917584 | 1.00 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL11967173 | 1.00 | BACE1 (1.00) | BACE1BACE2CTSD | |
| SCHEMBL20887615 | 0.94 | BACE1 (0.88) | BACE1BACE2 | |
| SCHEMBL19614962 | 0.94 | BACE1 (0.88) | BACE1BACE2 | |
| SCHEMBL19616597 | 0.94 | BACE1 (0.88) | BACE1BACE2 | |
| SCHEMBL11967128 | 0.94 | BACE1 (0.88) | BACE1BACE2CTSD | |
| SCHEMBL6917555 | 0.92 | BACE1 (0.85) | BACE1BACE2CTSD | |
| SCHEMBL11967145 | 0.91 | BACE1 (0.84) | BACE1BACE2CTSD | |
| SCHEMBL6916593 | 0.91 | BACE1 (0.84) | BACE1BACE2CTSD | |
| SCHEMBL11967132 | 0.91 | BACE1 (0.84) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079914-B2 | Fused aminodihydro-oxazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-14 | — | — | US | claimed |
| EP-2653473-A1 | Fused Aminodihydro-Oxazine Derivatives | Eisai R&D Management Co., Ltd. (JP) | 2013-10-23 | — | — | EP | claimed |
| EP-2456774-B1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | claimed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | Ambetex Pty Ltd (AU) | 2023-07-13 | — | — | US | disclosed |
| US-9079914-B2 | Fused aminodihydro-oxazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9079914-B2 | Fused aminodihydro-oxazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9079914-B2 | Fused aminodihydro-oxazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2653473-A1 | Fused Aminodihydro-Oxazine Derivatives | Eisai R&D Management Co., Ltd. (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2653473-A1 | Fused Aminodihydro-Oxazine Derivatives | Eisai R&D Management Co., Ltd. (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2456774-B1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2456774-B1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2456774-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011009898-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885CTSD 515/4885 |
| US-20230218629-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | TNNI3, TNNT2, TNNC1 | BACE1 5/4885BACE2 12/4885CTSD 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.